Introduction
============

More than 10% of the adult population in the United States suffers from chronic kidney disease (CKD) (Levey and Coresh [@b28]), and the prevalence increases with age with more than 35% of those over 60 affected. CKD is associated with various disease states, primarily old age, diabetes, hypertension, obesity, and cardiovascular disease, but can also result from infections and exposure to drugs or toxins. In the early stage, CKD is mostly asymptomatic, although associated with risk of cardiovascular morbidity and mortality. As kidney function deteriorates through more extensive damage to the organ it becomes impossible to reverse the progression to end-stage kidney failure, which is defined by glomerular filtration rate (GFR) of less than 15 mL/min per 1.73 m^2^. Complications of such low GFR include an increased risk of cardiovascular disease, acute kidney injury, infection, cognitive impairment, and impaired physical function (Levey and Coresh [@b28]), and require intervention in the form of dialysis or kidney transplantation. It is thus critical to find targets for intervention in the progression of CKD to end-stage kidney failure.

Collagens are extracellular matrix (ECM) proteins, which play a role in organ formation, growth, and homeostasis. Fibrosis results from abnormal accumulation of matrix, predominantly collagen, which is associated with loss of organ function as normal tissue is replaced by scar tissue (Wynn [@b59]). CKD is a prototypical example of progressive fibrosis leading to organ failure (Hewitson [@b22]; Boor et al. [@b10]; Zeisberg and Neilson [@b62]). Both glomerulosclerosis and tubulointerstitial fibrosis are involved in CKD, however, the latter is the better histological predictor of progression (Bohle et al. [@b9]). Increased expression of *Col1a2* and *Col3a1* have been previously described to correlate with aging, injury, and fibrotic changes in the kidney (Bielesz et al. [@b8]; Gaikwad et al. [@b17]; Fragiadaki et al. [@b16]), as well as in other systems (Wu and Chakravarti [@b58]; van Almen et al. [@b5]).

Numerous animal models have been described to study age-related alterations in the kidney (Baylis and Corman [@b7]). Many of the structural changes in the aged human kidney are observed in rats, such as degenerative changes in the proximal tubules and thickening of the glomerular basement membrane. Other notable functional deficits in the rat include proteinuria and reduced urine concentration (Haley and Bulger [@b21]; Sands [@b47]). Of note, the development of renal disease is more severe in males as compared to females (Baylis [@b6]; Sasser et al. [@b48]), and that nutrition affects age-related renal dysfunction (Zawada et al. [@b61]). In male Fischer 344 rats, we observe a progression of kidney deterioration similar to end-stage renal disease including severe glomerulosclerosis and interstitial fibrosis (Corman and Owen [@b14]). Lifelong caloric restriction will ameliorate this effect (Stern et al. [@b50]). Rat models present a well-characterized and invaluable tool to investigate age-related changes in the kidney, including consequences of glomerulosclerosis and fibrosis.

Given the development of glomerulosclerosis and tubulointerstitial fibrosis in the aging kidney, both of which are associated with increased ECM deposition, it was suggested that MMP activity would decrease during aging. In aging male Wistar kidneys, proximal tubules have been shown to have lower cysteine and metalloproteinase activity (Schaefer et al. [@b49]); similar results were seen in brush border--enriched fractions of male Sprague--Dawley rats (Reckelhoff and Baylis [@b41]). In both studies, however, the activities of specific MMPs were not characterized. However, in a microarray analysis of kidney samples from 74 patients between 27 and 92 years indicated a 2.90-fold increase in MMP-7 expression with increasing age (Rodwell et al. [@b44]). Interestingly, the fold change was the second largest. This finding has been confirmed in a separate study (Melk et al. [@b31]). Previous studies from our laboratory have indicated that MMP-7 is overexpressed in the aging rat kidney (Chen et al. [@b13]).

MMP-7 is the smallest member of the metalloproteinase family and has gained attention in the recent years for its role in abnormal tissue remodeling (Nagase and Woessner [@b37]). The secreted protein is minimally expressed in the adult, with the notable exceptions of the small intestine and bladder. MMP-7 is not detected in normal human renal tubular epithelium, but significant expression was seen in a number of pathologic states including polycystic kidney disease in humans and unilateral ureteral obstruction or acute folic acid nephropathy in mice (Surendran et al. [@b51]). It has been proposed as a new screening marker for kidney damage (Reich et al. [@b42]), cardiovascular complications in patients with CKD (Musial and Zwolinska [@b36]), and possibly for the prediction of kidney transplant rejection (Jovanovic et al. [@b25]; Rodder et al. [@b43]). In addition, MMP-7 may be involved in the development of fibrosis in the lung (Zuo et al. [@b64]; Rosas et al. [@b46]) and liver (Huang et al. [@b23]). There have been reports of MMP inhibitors, specifically doxycycline, successfully reducing proteinuria in patients with diabetic nephropathy (Aggarwal et al. [@b2]) and glomerulonephritis (Ahuja [@b3]), suggesting that MMPs play a pathogenic role in the development of chronic renal dysfunction. In this study, we investigated the mechanistic link between MMP-7 overexpression and fibrosis in the aging kidney.

Material and Methods
====================

Animals
-------

Male Fisher 344 rats were obtained from the National Institute of Aging, Bethesda, MD, and housed in the Animal Facilities at the College of Medicine, Texas A&M Health Science Center or the University of Missouri School of Medicine. All animal protocols were submitted and approved by the Texas A&M and University of Missouri Animal Care and Use Committee in accordance with the NIH.

Animals were purchased at the indicated ages and housed for a week before being placed in metabolic cages (Tecniplast, Exton, PA) 18 h prior to sacrifice. Animals were fed ad libitum (AL) or calorie restricted (CR); CR was initiated at 14 weeks of age at 10% restriction, increased to 25% restriction at 15 weeks, and to 40% restriction at 16 weeks, which was subsequently maintained throughout the remaining life of the animal. The animal room was temperature controlled and maintained on a 12:12 h light:dark cycle. Following anesthesia (ketamine 87 mg/kg and xylazine 13 mg/kg body weight), rats were sacrificed by heart puncture, the abdominal cavity was opened, and the kidneys were removed and weighed. Kidneys were sliced into 1-mm-thick sections and either snap frozen in liquid nitrogen or frozen in liquid nitrogen--cooled optimal cutting temperature compound (Tissue-Tek; Sakura Finetek, Torrance, CA) for cryosectioning or fixed in formalin and paraffin embedded for immunohistochemistry.

MMP-7 clones
------------

The full-length wild-type human MMP7 (NM_002423) clone in pCMV6-Neo was purchased from OriGene (Rockville, MD). The sequence was altered by oligonucleotide-directed mutagenesis exchange reactions as described previously (Geiser et al. [@b19]) using QuickChange II Site-Directed Mutagenesis Kit (Stratagene/Agilent Technologies, Santa Clara, CA). The active mutant with a substitution of valine to glycine at amino acid 92 (Witty et al. [@b56]) was generated using the following oligonucleotides: antisense 5′- CAG ATG TGG AGG GCC AGA TGT TG-3′, and sense 5′- CAA CAT CTG GCC CTC CAC ATC TG-3′. The inactive mutant with a substitution of glutamic acid to glutamine at amino acid 216 was generated using the following oligonucleotides: antisense 5′- ATG GCC AAG TTG ATG AGT TGC-3′ and sense 5′- GCA ACT CAT CAA CTT GGC CAT-3′. Mutations were confirmed by sequencing.

Cell culture
------------

NRK-52E cells were obtained from the ATCC (catalog \# CRL-1571; Manassas, VA) and maintained in DMEM/F12 1:1 (Dubelcco\'s modified, Eagle medium/Ham\'s F-12 Nutrient Mix; Gibco, Life Technologies, Grand Island, NY) supplemented with 5% FBS (fetal bovine serum; Hyclone, Thermo Fisher Scientific), penicillin/streptomycin, and gentamicin (Gibco, Life Technologies). The cells were transfected with the full-length human wild-type MMP7 (NM_002423), active and inactive mutants and control vector pCMV6-Neo (OriGene) using Lipofectamine 2000 (Invitogen, Life Technologies) and subjected to selection with 350 μg/mL Geneticin (Gibco, Life Technologies) in DMEM/F12 with 10% FBS and no other antibiotics. In certain experiments, conditioned medium was collected after 24 h and concentrated using Vivaspin columns with a molecular weight cut-off of 10 kDa (Sartorius, Bohemia, NY).

Western blot
------------

Subconfluent cells were washed twice with ice-cold PBS (phosphate buffered saline; Gibco, Life Technologies) and lysed with 10-mmol\\L Tris-1% sodiumdodecyl sulphate (SDS) buffer with Halt Protease/Phosphatase inhibitor. Cells were scraped and incubated for 15 min at 4°C on a rocker. Cells were further disrupted by passing through a 20-gauge needle and spun at 12,000*g* for 15 min at 4°C. Tissue lysates were isolated using a 10-mmol\\L Tris-1% SDS buffer supplemented with Halt Protease Inhibitor Cocktail (Thermo Fisher-Pierce, Rockford, IL). Protein concentration was determined by absorbance readings at 280 nm on a Nanodrop 2000c spectrophotometer (Thermo Fisher Scientific).

The following antibodies were used: anti-MMP7: GTX104658 1:1000 (GeneTex, Irvine, CA), anti-β actin A2228 1:2000 (Sigma, St. Louis, MO), ERK (4695), P-ERK (4370), src (2102), P-src (6943), protein kinase A (PKA) (4782), and P-PKA (4781) 1:1000 (all Cell Signaling Technology, Beverly, MA). Goat anti-rabbit horseradish peroxidase (HRP) conjugate and goat anti-mouse HRP conjugate (Jackson ImmunoResearch Laboratories, West Grove, PA) were used at 1:20,000 dilutions. Blots were developed using West Femto (Thermo Fisher-Pierce) and imaged using the ChemiDoc imaging system (Bio-Rad, Hercules, CA).

Immunohistochemistry
--------------------

Kidneys were sliced with a razor blade into four sagittal sections and placed in 4% paraformaldehyde for 24 h. The sections were subsequently rinsed repeatedly with PBS, and placed in 70% ethanol for embedding. Sections were deparaffinized by xylene incubation for 12 min and rehydrated in a graded series of ethanol (95%, 80%, 70%, and 50% ethanol) for 5 min each, and then washed with PBS for 10 min. Slides were stained for collagen deposition using the NovaUltra Sirius Red Stain Kit, IHC WORLD, Woodstock, MD.

Immunofluorescence
------------------

NRK cells were grown on glass coverslips in 6-well plates. Cells were washed with PBS, fixed in 4% paraformaldehyde for 10 min, permeabilized with 1% Triton X-100 for 10 min, blocked with Background Sniper (Biocare Medical, Concord, CA) for 10 min, washed with tris buffered saline, and incubated with the following antibodies: MMP7 (SAB4501894, Sigma-Aldrich, St. Louis, MO; 1:100), src (2102, 1:100), P-src (6943, 1:100), ERK (4695, 1:100), P-ERK (4370, 1:200), PKA (4782, 1:100), and P-PKA (4781, 1:100) (Cell Signaling Technology) in 1% BSA (bovine serum albumin; Thermo Fisher Scientific) in PBS for 1 h at room temperature (RT). Negative control for secondary antibody was only incubated with Fluorescence Antibody Diluent (Biocare Medical). Coverslips were then washed with PBST (PBS with 0.2% Tween 20) and incubated with goat anti-rabbit secondary antibody DyLight 594 (Biocare Medical) 1:50 for 1 h at RT. Coverslips were then washed once and mounted on slides with Fluoroshield with 4′,6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich).

Cells were imaged on an Olympus IX51 microscope with a UC50 digital camera using cellSense software (Olympus, Center Valley, PA) at equal exposure times.

In-cell Western blot
--------------------

Subconfluent cells grown in 96-well opaque clear bottom cell culture plates were washed with PBS and fixed with 4% paraformaldehyde for 20 min. Cells were permeabilized with 0.1% Triton X-100 and endogenous peroxidase was quenched with H~2~O~2~ and NaN~3~ for 20 min. Cells were blocked with normal goat serum for 1 h and incubated with primary antibody at a 1:100 dilution overnight followed by washing as above and addition of secondary antibody at 1:1000 for 1 h. Blots were developed using West Femto (Pierce, Thermo Fisher Scientific), and chemiluminescence was read using a Synergy HT microplate reader with Gen5 software (BioTek, Winooski, VT) and imaged with ChemiDoc imaging system (Bio-Rad). Cells were then washed with PBS, stained with Janus Green stain for 1 min, washed and eluted in 100% ethanol. Absorbance was read at 594 nm. Chemiluminescence signal was normalized per cell number, and the negative control (secondary antibody only) signal was subtracted from an average of three wells per antibody. Expression was then reported relative to the β-actin signal.

RNA isolation and cDNA synthesis
--------------------------------

RNA was isolated using the RNeasy kit (Qiagen, Valencia, CA) for animal tissue analysis and sequencing samples, and with the Tissue/cell total RNA mini kit (EZ BioResearch, St. Louis, MO) for inhibitor studies. Snap-frozen kidney tissues were lysed with RNeasy lysis (RTL) buffer (Qiagen) supplemented with β-mercaptoethanol and homogenized using a motorized pellet pestle (Kontes, Vineland, NJ) followed by centrifugation in the Qiashredder (Qiagen). Cultured NRK-52E cells were trypsinized, pelleted, and lysed with RTL buffer (Qiagen) supplemented with β-mercaptoethanol and passed 5 times through a 20-gauge needle. On-column DNase digestion was performed for both tissues and cells. RNA concentration and quality was determined by spectrophotometry on a Nanodrop 2000c and confirmed by agarose gel electrophoresis. cDNA was generated using the iScript cDNA Synthesis Kit (Bio-Rad) for initial MMP and TIMP screening, and the High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, Life Technologies) was used for later experiments.

Real-time polymerase chain reaction
-----------------------------------

Initial MMP and TIMP screening was performed using the iCycler iQ real-time polymerase chain reaction (PCR) detection system (Version 3.1; Bio-Rad) and iQ SYBR® Green Supermix (Bio-Rad). Genes of interest were targeted using specific RT² Real-Time PCR primer sets (SuperArray; SABiosciences, Qiagen). Relative quantitation was performed using the ΔΔCt method in which the quantity of target gene mRNA in each experimental sample (young, aged-AL or aged-CR) relative to an internal standard (ß-actin mRNA) is normalized to an arbitrary reference sample (Universal Rat Reference RNA; Stratagene) (Akintola et al. [@b4]). In subsequent experiments, we used custom primer/probe Taqman® Assays (Applied Biosystems, Life Technologies) and the Sso Fast mix (Bio-Rad) with the CFX96 Touch real-time PCR system (Bio-Rad). Analysis was performed using the ΔΔCt method relative to Casc3 and ß-actin.

Illumina sequencing
-------------------

RNA from the normal rat kidney parent cell-line NRK-52E, as well as cells stably expressing wild-type MMP7, active mutant MMP7, and control vector, was submitted for high-throughput sequencing. A mRNA-focused, bar-coded library was generated using the TruSeq kit (Illumina, San Diego, CA) and analyzed using the HiSeq 2000 platform from Illumina at the DNA Core Facility at the University of Missouri. The sequencing reaction yielded ∼7.5 Gb of data, corresponding to around 30 million 50-base reads per sample across the whole transcriptome. The Informatics Research Core Facility at the University of Missouri aligned the reads against the rat genome (Rattus norvegicus RGSC3.4; Ensemble, Hinxton, UK) and analyzed them using Bowtie (Langmead and Salzberg [@b27]), TopHat and Cufflinks (Trapnell et al. [@b53]) software. Differential expression values defined as fragments per kilobase of transcript per million mapped reads with a false discovery--corrected *P*-value equal or lower than 0.05 were considered significant. The raw data from our Illumina high-throughput sequencing has been deposited in the Sequence Read Archive (SRA) with the National Center for Biotechnology Information (Bethesda, MD) under the project PRJNA213322, accession number SRP02851, experiment MMP7, accession number SRX327868, and will be made available upon publication of this manuscript.

Inhibitors
----------

The inhibitors used in this study were all purchased from Calbiochem (Darmstadt, Germany): GM6001 (MMPs), LY294002 (PI3K), UO126 (MEK \[mitogen-activated protein kinase kinase\]), 4-amino-5-(4-chlorophenyl)-7-(dimethylethyl)pyrazolo\[3,4-d\]pyrimidine (PP2) (src), SB203580 (4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole) and 2-(4-Chlorophenyl)-4-(4-fluorophenyl)-5-pyridin-4-yl-1,2-dihydropyrazol-3-one (p38), FR180204 (ERK1/2), Staurosporine (PKA/protein kinase C \[PKC\]), KT5720 (PKA), and Bisindolylmaleimide I (PKC). Cells were grown in 6- or 12-well plates in full medium as described in Cell culture above. Upon reaching 90% confluency, cells were washed once with serum-free DMEM/F12 and treated with indicated concentrations of inhibitors in serum-free medium.

Statistics
----------

For mRNA expression, in-cell Western, and enzymatic assay results, a two-tailed *t*-test assuming two-sample equal variance was performed with *P*-values \<0.05 considered statistically significant.

Results
=======

Age-related overexpression of MMP-7
-----------------------------------

Given the importance of MMPs in acute and chronic renal pathophysiologies (Catania et al. [@b12]), we examined the mRNA expression of all MMPs and TIMPs in young (4 month-old), aged, 24-month-old AL fed, and aged CR rat kidneys by quantitative PCR. Using rat-specific primers, we found expression of many MMPs that have not yet been linked to the kidney, including MMP-1, -16, -17, -20, -21, and -25 (Fig. [1](#fig01){ref-type="fig"}A). In contrast to a previous report investigating human MMP-2 and MMP-24 (Romanic et al. [@b45]), expression of MMP-15 and -24 was not detected in the rat kidney. Importantly, we identified several MMPs whose gene expression was significantly changed as a function of aging, including MMP-2, -3, -7, -9, -12, -13, -14, -16, -17, -19, -20, -23, and -25, as well as TIMP-1. Of these, the increased expression of MMP-2, -7, -9, -12, -13, -14, -16, -20, -23, and -25 was attenuated by caloric restriction, as was TIMP-1. As MMP-7 exhibited the most dramatic increase in the aged animals and is overexpressed in the aging human kidney (Rodwell et al. [@b44]; Melk et al. [@b31]), we examined MMP-7 expression over an extensive time course. At 16 months expression was significantly upregulated, and increased to over 500-fold upregulation in 2-year-old animals (Fig. [1](#fig01){ref-type="fig"}B). Importantly, increased gene expression correlated with increased protein expression as assessed by Western blot (Fig. [1](#fig01){ref-type="fig"}C). The temporal pattern of MMP-7 overexpression, and the finding that it is not overexpressed in caloric restriction controls, suggests that MMP-7 may play a pathogenic role in the development of chronic renal dysfunction.

![Age-dependent changes in MMP/TIMP expression in the kidney. (A) Relative expression of MMPs and TIMPs in young (4 AL), old (24 AL), and calorie-restricted animals (24 CR) as determined by real-time PCR. ß-actin was used as the reference gene. Expression of MMP-2, -3, -7, -9, -12, -13, -14, -16, -17, -19, -20, -23, and -25, as well as TIMP-1 changed significantly as a function of age. Of these, the increased expression of MMP-2, -7, -9, -12, -13, -14, -16, -20, -23, and -25 was attenuated by caloric restriction, as was TIMP-1, with *P* \< 0.05. (B) MMP-7 expression in aging rat kidneys is significantly increased as early as 16 months. \**P* \< 0.05. (C) MMP-7 protein expression is increased in the 24-month-old rat kidney, but not CR controls. Each lane represents a lysate from an individual animal.](phy20001-e00090-f1){#fig01}

MMP-7 overexpression: collagen expression
-----------------------------------------

In order to delineate the effects of MMP-7 overexpression in the kidney, we stably overexpressed MMP-7 in NRK-52E cells. As epithelial cells do not activate MMP-7 in vitro (Witty et al. [@b56]), we overexpressed wild-type MMP-7, an active mutant of MMP-7, and a catalytically inactive mutant. The active mutant has a point mutation resulting in a valine to glycine substitution at position 92 (Fig. [2](#fig02){ref-type="fig"}). This mutation in the prodomain allows for an autocatalytic cleavage of the zymogen to produce a catalytically active MMP-7. The inactive mutant has a point mutation in the catalytic domain at position 216. Overexpressed MMP-7 was detectable in the NRK-52E cells and was secreted into the medium (Fig. [2](#fig02){ref-type="fig"}). In conditioned medium from wild-type and the inactive mutant overexpressing NRK-52E cells, only the 30 kDa zymogen was visible on the Western blot. Expression of the active form was lower as determined by real-time PCR and Western blot, and bands representing both the 30 kDa pro- and a 18 kDa active form were detected. Each of the MMP-7 overexpressing cells exhibited comparable doubling times, which were shorter than those of the parent NRK-52E cell line, probably due to the strong cytomegalovirus promoter in the vector (data not shown). It is important to note that the relative expression of pro-MMP-7 appears to be higher in the wild-type and inactive mutant constructs than in the active mutant, which still expressed pro-MMP-7.

![Generation of MMP-7 overexpressing cell lines. Normal rat kidney cells (NRK-52E) were stably transfected with full-length human MMP-7 (WT), a catalytically active mutant and an inactive mutant form. Immunofluorescence staining with anti-MMP-7 antibody in vector and MMP-7 WT overexpressing cells, DAPI counterstain (bottom panels). Concentrated conditioned medium immunoblotted with anti-MMP-7 antibody shows bands for proform ∼30 kDa and active form ∼18 kDa (insert).](phy20001-e00090-f2){#fig02}

High-throughput sequencing of mRNA libraries generated from MMP-7 overexpressing cells yielded promising target genes, including *Col1a2* and *Col3a1*, interestingly, in both the WT and active mutant MMP-7 overexpressing cells (Fig. [3](#fig03){ref-type="fig"}A; Table[1](#tbl1){ref-type="table"}). While WT overexpressing cells had the largest increase in collagen expression, the catalytic activity of MMP-7 may be important given the findings that the active mutant cells also were characterized by collagen overexpression and that this effect was significantly decreased in the inactive mutant cells. Increased collagen deposition is characteristic of the aging rat kidney (Fig. [3](#fig03){ref-type="fig"}B). As expected, expression of both collagens increased with age and paralleled the temporal changes in MMP-7 overexpression (Fig. [3](#fig03){ref-type="fig"}C).

![Relationship between MMP-7 and collagen expression. (A) *Col1a2* and *Col3a1* expression changes in MMP-7 overexpressing cell as determined by real-time PCR. Casc3 was used as the reference gene. The upregulation determined by Illumina sequencing was 3.9- and 2.1-fold for *Col1a2* and *Col3a1* in WT cells, and 5.0 and 1.4 in active mutant MMP-7 cells (A1) compared to vector control. (B) Fibrotic changes are visualized by sirius red staining of collagen deposition. Caloric-restricted (CR) 24-month-old rats are comparable to young, 4-month control animals (top panels). Confirmation of increased collagen levels in older animals as determined by the hydroxyproline assay (bottom graph). \**P* \< 0.05 relative to 4 AL, \#relative to 24 AL. (C) *Col1a2* and *Col3a1* expression (left *y*-axis) correlates with MMP-7 expression (right *y*-axis) in individual F344 rats and increases with age as determined by real-time PCR. Casc3 was used as the reference gene.](phy20001-e00090-f3){#fig03}

###### 

Vector vs MMP-7 WT

  Test_id              Gene_id              Gene           Locus                     Vector      WT          Log2 (fold_change)   Test_stat       *P*-value     *q*-value     Fold change     
  -------------------- -------------------- -------------- ------------------------- ----------- ----------- -------------------- --------------- ------------- ------------- --------------- -----------------------------------------------------------------------------------------------------
  ENSRNOT00000046954   ENSRNOG00000034295   --             6:6947525--6995752        12.881      1.0758      −3.58177             5.0234          5.08E−07      0.000179958   0.08            no protein, pseudogene in Renal function QTL16
  ENSRNOT00000017623   ENSRNOG00000012939   ABCA7_RAT      7:11203982--11222960      1.20463     3.87364     1.6851               −3.89959        9.64E−05      0.0143744     3.22            ATP-binding cassette sub-family A member 7
  ENSRNOT00000064886   ENSRNOG00000012939   ABCA7_RAT      7:11203982--11222960      2.86713     0.324656    −3.14262             3.83916         0.000123456   0.0175413     0.11            ABC transporter, conserved site, ATPase, AAA+type, core, ABC transporter-like
  ENSRNOT00000064572   ENSRNOG00000001404   Agfg2          12:19716014--19752171     0           3.67817     1.79769e+308         1.79769e+308    1.74E−05      0.0036515     up              Arf-GAP domain and FG repeats-containing protein 2
  ENSRNOT00000025258   ENSRNOG00000018598   Ankrd1         1:240316122--240324804    40.6488     10.8954     −1.89949             7.22162         5.14E−13      7.21E−10      0.27            ankyrin repeat domain 1 (cardiac muscle)
  ENSRNOT00000049698   ENSRNOG00000006094   Cd44           3:88022982--88110352      11.8848     1.42914     −3.0559              3.65923         0.000252976   0.0303702     0.12            CD44
  ENSRNOT00000036025   ENSRNOG00000021285   CELSR1         7:123900402--124036122    7.81533     13.788      0.819038             −3.73805        0.00018545    0.0239456     1.76            cadherin, EGF LAG seven-pass G-type receptor 1 (flamingo homolog, Drosophila)
  ENSRNOT00000016423   ENSRNOG00000011292   Col1a2         4:29393550--29428568      2.90803     11.3761     1.96789              −6.34732        2.19E−10      1.75E−07      3.91            Collagen alpha-2(I) chain
  ENSRNOT00000004956   ENSRNOG00000003357   Col3a1         9:44281581--44317827      115.743     243.059     1.07038              −4.5815         4.62E−06      0.00121382    2.10            collagen, type III, alpha 1
  ENSRNOT00000019501   ENSRNOG00000014350   Cyr61          2:243824302--243827262    331.587     183.356     −0.854743            3.97211         7.12E−05      0.0113395     0.55            Cysteine-rich angiogenic inducer 61
  ENSRNOT00000057522   ENSRNOG00000030213   D3ZEY5_RAT     8:72196263--72365798      0.674155    0           −1.79769e+308        1.79769e+308    0.00028722    0.0334497     not expressed   SF-assemblin, Vacuolar protein sorting-associated protein
  ENSRNOT00000047772   ENSRNOG00000037380   D3ZQW7_RAT     1:88001743--88067218      101.201     7.59185     −3.73663             9.86554         0             0             0.08            Ribosomal protein S5
  ENSRNOT00000044096   ENSRNOG00000006028   D4A709_RAT     7:127403424--127423259    3.1215      7.69981     1.30258              −3.63814        0.00027461    0.0324075     2.47            Tubulin gamma complex associated protein 6, Tubgcp6
  ENSRNOT00000051316   ENSRNOG00000012209   E9PTG4_RAT     15:38658775--38687199     4.36822     0           −1.79769e+308        1.79769e+308    6.25E−05      0.0101695     not expressed   Cytidine deaminase-like, APOBEC/CMP deaminase, zinc-binding, CMP/dCMP deaminase, zinc-binding
  ENSRNOT00000044776   ENSRNOG00000018121   E9PTW0_RAT     2:58667033--58720040      0.746746    85.5269     6.83962              −11.8052        0             0             114.53          Ribosomal protein S5, N-terminal
  ENSRNOT00000019361   ENSRNOG00000014361   Edn1           17:28303885--28309775     54.8802     23.6102     −1.21687             4.88724         1.02E−06      0.000329694   0.43            endothelin 1
  ENSRNOT00000013608   ENSRNOG00000009439   Eef1a1         8:83463586--83466816      3348.41     3292.51     −0.0242881           4.72225         2.33E−06      0.000676657   0.98            eukaryotic translation elongation factor 1 alpha 1
  ENSRNOT00000032780   ENSRNOG00000001469   Eln            12:23033656--23076086     137.942     329.623     1.25675              −4.73083        2.24E−06      0.000654139   2.39            elastin
  ENSRNOT00000023825   ENSRNOG00000017719   F1M599_RAT     4:123811374--123820389    0.137075    13.1672     6.58584              −7.86897        3.55E−15      6.95E−12      96.06           novel protein, similar to glutamate receptor, ionotropic, N-methyl D-aspartate-like 1A (Grinl1a)
  ENSRNOT00000052149   ENSRNOG00000019579   F1M6R5_RAT     8:61472271--61516975      3.44162     0           −1.79769e+308        1.79769e+308    0.000221007   0.0273718     not expressed   YjeF-related protein, N-terminal
  ENSRNOT00000005709   ENSRNOG00000004290   Grb10          14:92814796--92911442     0           3.04998     1.79769e+308         1.79769e+308    0.000286745   0.0334497     up              Growth factor receptor-bound protein 10
  ENSRNOT00000064187   ENSRNOG00000007000   Grhl2          7:72742858--72872350      0.0605663   0.653535    3.43168              −4.74934        2.04E−06      0.000605972   10.79           CP2 transcription factor, grainyhead-like 2 (Drosophila)
  ENSRNOT00000015894   ENSRNOG00000011847   Grk4           14:81648002--81722480     0           1.66054     1.79769e+308         1.79769e+308    0.000179469   0.023406      uo              G protein-coupled receptor kinase 4
  ENSRNOT00000016174   ENSRNOG00000012119   LOC690209      8:14245341--14246673      20.9934     6.87195     −1.61114             4.89442         9.86E−07      0.000319748   0.33            similar to NIMA (never in mitosis gene a) -related exp NPR3
  ENSRNOT00000004684   ENSRNOG00000003532   Magea11        X:144114831--144120816    1.28968     22.0279     4.09425              −9.23241        0             0             17.08           Melanoma-associated antigen 11
  ENSRNOT00000000169   ENSRNOG00000000156   Megf6          5:170848978--171078739    22.4684     40.0213     0.832874             −3.78871        0.000151431   0.020509      1.78            multiple EGF-like-domains 6
  ENSRNOT00000067408   ENSRNOG00000006699   Mlh3           6:109280909--109318893    0           0.941301    1.79769e+308         1.79769e+308    0.000154966   0.0208462     up              DNA mismatch repair protein Mlh3
  ENSRNOT00000046803   ENSRNOG00000007948   Nf2            14:85415141--85508807     0           4.22702     1.79769e+308         1.79769e+308    6.89E−05      0.0110418     up              neurofibromin 2 (merlin)
  ENSRNOT00000046152   ENSRNOG00000021996   Nlrp4          1:66797942--66825101      0.336655    2.11805     2.6534               −4.92581        8.40E−07      0.000277953   6.29            NACHT, LRR and PYD domains-containing protein 4
  ENSRNOT00000010779   ENSRNOG00000008141   Nppb           5:165062347--165063650    16.0836     3.25884     −2.30316             4.49445         6.98E−06      0.00172925    0.20            natriuretic peptide B
  ENSRNOT00000060426   ENSRNOG00000010477   Pomt1          3:11348785--11366632      0           5.56385     1.79769e+308         1.79769e+308    0.000173499   0.0227703     up              Protein O-mannosyl-transferase 1
  ENSRNOT00000055032   ENSRNOG00000013267   Pric285        3:170368820--170382086    0           0.57973     1.79769e+308         1.79769e+308    0.000232451   0.0285096     up              Peroxisomal proliferator-activated receptor A interacting complex 285
  ENSRNOT00000052290   ENSRNOG00000032703   Rasgrp3        6:19808452--19871923      8.30593     4.20947     −0.980502            3.51371         0.000441899   0.0463619     0.51            Ras guanyl-releasing protein 3
  ENSRNOT00000059819   ENSRNOG00000002144   Sec3l1         14:33883343--33920857     8.24032     0.596241    −3.78873             3.77394         0.00016069    0.0215016     0.07            exocyst complex component 1
  ENSRNOT00000001916   ENSRNOG00000001414   Serpine1       12:20931995--20942374     62.8455     33.8617     −0.892153            4.18393         2.87E−05      0.00547625    0.54            Serpine 1
  ENSRNOT00000063959   ENSRNOG00000020138   Slc4a3         9:74823768--74835860      2.77433     0           −1.79769e+308        1.79769e+308    1.44E−05      0.00314476    not expressed   Anion exchange protein 3
  ENSRNOT00000039221   ENSRNOG00000026607   Tnfsf18        13:77136963--77145251     35.8281     8.85273     −2.0169              4.69464         2.67E−06      0.000754331   0.25            Tumor necrosis factor ligand superfamily member 18
  ENSRNOT00000011530   ENSRNOG00000008717   --             6:127258746--127462319    68.0545     0.142029    −8.90436             10.8992         0             0             479.16          novel transcript within Urinary albumin excretion QTL 7
  ENSRNOT00000033844   ENSRNOG00000021292   --             17:59022844--59275923     27.9701     6.97332     −2.00397             5.82617         5.67E−09      3.33E−06      4.01            retinoblastoma binding protein 4; similar to Chromatin assembly factor 1 subunit CG4236-PA
  ENSRNOT00000034355   ENSRNOG00000026168   --             8:125535679--125536042    25.0815     0           −1.79769e+308        −1.79769e+308   1.70E−05      0.00357667    up              Novel retrotransposed, within Collagen induced arthritis QTL 6
  ENSRNOT00000017623   ENSRNOG00000012939   ABCA7_RAT      7:11203982--11222960      3.5788      1.20463     −1.57089             3.58895         0.000332008   0.0372815     2.97            ATP-binding cassette sub-family A member 7
  ENSRNOT00000064572   ENSRNOG00000001404   Agfg2          12:19716014--19752171     2.82724     0           −1.79769e+308        −1.79769e+308   0.000109477   0.0159041     up              arf-GAP domain and FG repeats-containing protein 2
  ENSRNOT00000025258   ENSRNOG00000018598   Ankrd1         1:240316122--240324804    19.6078     40.6488     1.05179              −4.35548        1.33E−05      0.00294741    0.48            Ankyrin repeat domain-containing protein 1
  ENSRNOT00000026058   ENSRNOG00000019253   Bcar1          19:41646189--41669234     24.8368     53.8451     1.11634              −3.54057        0.00039926    0.0429581     0.46            Breast cancer anti-estrogen resistance protein 1
  ENSRNOT00000049698   ENSRNOG00000006094   Cd44           3:88022982--88110352      2.12927     11.8848     2.48069              −3.68657        0.000227297   0.0280383     0.18            CD44 antigen
  ENSRNOT00000016423   ENSRNOG00000011292   Col1a2         4:29393550--29428568      14.5862     2.90803     −2.32649             7.61096         2.73E−14      4.69E−11      5.02            Collagen alpha-2(I) chain
  ENSRNOT00000068558   ENSRNOG00000033169   Cpeb4          10:15968781--16026700     2.62906     0           −1.79769e+308        −1.79769e+308   5.69E−05      0.00947819    up              cytoplasmic polyadenylation element-binding protein 4
  ENSRNOT00000029132   ENSRNOG00000030213   D3ZEY5_RAT     8:72196263--72365798      1.86717     0.48052     −1.95819             3.49363         0.000476492   0.0491335     3.89            similar to SF-assemblin, Vacuolar protein sorting-associated protein
  ENSRNOT00000057522   ENSRNOG00000030213   D3ZEY5_RAT     8:72196263--72365798      0           0.674155    1.79769e+308         1.79769e+308    0.00028722    0.0334497     not expressed   similar to vsp13c, SF-assemblin, Vacuolar protein sorting-associated protein
  ENSRNOT00000067052   ENSRNOG00000027569   D3ZJK6_RAT     7:110316544--110793515    1.4168      9.28808     2.71274              −3.55196        0.000382373   0.0415763     0.15            trafficking protein particle complex 9
  ENSRNOT00000047364   ENSRNOG00000000922   D3ZTR4_RAT     12:28003490--28028905     48.1732     22.6988     −1.08561             3.77329         0.000161109   0.0215162     2.12            similar to SUMF2 sulfatase modifying factor 2
  ENSRNOT00000013608   ENSRNOG00000009439   Eef1a1         8:83463586--83466816      3263.17     3348.41     0.0371986            −7.19883        6.07E−13      8.36E−10      0.97            Elongation factor 1-alpha 1
  ENSRNOT00000023825   ENSRNOG00000017719   F1M599_RAT     4:123811374--123820389    12.497      0.137075    −6.51047             7.7679          7.99E−15      1.47E−11      91.17           similar to polymerase (RNA) II (DNA directed) polypeptide M
  ENSRNOT00000056983   ENSRNOG00000006738   Fbxo32         7:94909567--94942444      0           1.83838     1.79769e+308         1.79769e+308    0.000205778   0.02596       not expressed   F-box only protein 32
  ENSRNOT00000018788   ENSRNOG00000014029   Klhl13         X:10344240--10424664      13.0508     4.89107     −1.41592             3.49066         0.000481835   0.0494691     2.67            kelch-like 13,BTB and kelch domain containing 2
  ENSRNOT00000063868   ENSRNOG00000014029   Klhl13         X:10344240--10424664      0           3.17109     1.79769e+308         1.79769e+308    0.000349141   0.0387204     not expressed   kelch-like 13
  ENSRNOT00000007696   ENSRNOG00000005869   LOC498453      15:11865466--12045333     8.80749     0           −1.79769e+308        −1.79769e+308   4.27E−07      0.000156012   up              similar to transcription elongation factor A 1 isoform 2
  ENSRNOT00000016991   ENSRNOG00000012495   Podxl          4:58611905--58658598      0.458957    0.0620132   −2.88771             4.09568         4.21E−05      0.00742765    7.40            Podocalyxin
  ENSRNOT00000000725   ENSRNOG00000000593   Rev3l          20:43870508--44042379     3.12343     0.529002    −2.56179             4.99287         5.95E−07      0.000206406   5.90            DNA polymerase zeta catalytic subunit, REV3-like
  ENSRNOT00000063936   ENSRNOG00000033389   Susd2          20:13435256--13442683     2.35239     0           −1.79769e+308        −1.79769e+308   7.25E−07      0.000244074   up              sushi domain-containing protein 2
  ENSRNOT00000046954   ENSRNOG00000034295   --             6:6947525--6995752        11.0197     1.0758      −3.35661             4.66138         3.14E−06      0.000872923   10.24           novel transcript, within intron of Potassium voltage-gated channel subfamily G member 3, Kcng3
  ENSRNOT00000034355   ENSRNOG00000026168   --             8:125535679--125536042    25.0815     0.409245    −5.93751             5.19284         2.07E−07      8.40E−05      61.29           novel transcript, retrotransposed, no protein prouct
  ENSRNOT00000033844   ENSRNOG00000021292   --             17:59022844--59275923     27.9701     8.30695     −1.75149             5.35403         8.60E−08      3.87E−05      3.37            retinoblastoma binding protein 4; similar to Chromatin assembly factor 1 subunit CG4236-PA
  ENSRNOT00000011530   ENSRNOG00000008717   --             6:127258746--127462319    68.0545     0.146856    −8.85614             11.2454         0             0             463.41          novel transcript within Urinary albumin excretion QTL 7
  ENSRNOT00000068558   ENSRNOG00000033169   Cpeb4          10:15968781--16026700     2.62906     0           −1.79769e+308        −1.79769e+308   5.69E−05      0.00947819    up              cytoplasmic polyadenylation element-binding protein 4
  ENSRNOT00000018888   ENSRNOG00000014048   CYLD_RAT       19:19617011--19644586     0           4.1787      1.79769e+308         1.79769e+308    1.65E−05      0.00350119    not expressed   Ubiquitin carboxyl-terminal hydrolase CYLD
  ENSRNOT00000012501   ENSRNOG00000030213   D3ZEY5_RAT     8:72196263--72365798      1.60088     3.96778     1.30946              −4.14081        3.46E−05      0.00634453    0.40            similar to VPS13C, vacuolar protein sorting 13 homolog C (S. cerevisiae)
  ENSRNOT00000067052   ENSRNOG00000027569   D3ZJK6_RAT     7:110316544--110793515    1.4168      9.74414     2.7819               −3.62734        0.000286351   0.0334497     0.15            trafficking protein particle complex 9
  ENSRNOT00000047772   ENSRNOG00000037380   D3ZQW7_RAT     1:88001743--88067218      104.886     7.59185     −3.78823             10.0102         0             0             13.82           Uncharacterized protein, similar to ribosomal protein S5
  ENSRNOT00000042105   ENSRNOG00000032471   D3ZYV8_RAT     14:112127247--112174996   1.08329     7.32505     2.75741              −3.49259        0.000478367   0.0492765     0.15            ankyrin repeat and SOCS box protein 3
  ENSRNOT00000044096   ENSRNOG00000006028   D4A709_RAT     7:127403424--127423259    3.01893     7.69981     1.35079              −3.71936        0.000199731   0.0253235     0.39            tubulin, gamma complex associated protein 6
  ENSRNOT00000065458   ENSRNOG00000002152   Dcun1d4        14:37051132--37128945     1.84175     6.03693     1.71274              −3.94183        8.09E−05      0.0125547     0.31            DCN1-like protein 4; defective in cullin neddylation 1, domain containing 4
  ENSRNOT00000051316   ENSRNOG00000012209   E9PTG4_RAT     15:38658775--38687199     5.20533     0           −1.79769e+308        −1.79769e+308   1.18E−05      0.00268048    up              cytidine and dCMP deaminase domain containing 1
  ENSRNOT00000044776   ENSRNOG00000018121   E9PTW0_RAT     2:58667033--58720040      0.305094    85.5269     8.13098              −10.5805        0             0             0.00            Ribosomal protein S5
  ENSRNOT00000020573   ENSRNOG00000015133   F1M0L3_RAT     8:47759174--47834586      2.13606     5.07054     1.24719              −4.08208        4.46E−05      0.00781665    0.42            Myeloid/lymphoid or mixed-lineage leukemia (Mapped)Uncharacterized protein
  ENSRNOT00000064187   ENSRNOG00000007000   Grhl2          7:72742858--72872350      0.106551    0.653535    2.61672              −3.99644        6.43E−05      0.0104084     0.16            grainyhead-like protein 2 homolog
  ENSRNOT00000004460   ENSRNOG00000003345   LOC302762      X:77009878--77012222      0.088109    0.749615    3.08879              −3.83252        0.000126838   0.017912      0.12            PREDICTED: DDB1- and CUL4-associated factor 8-like, similar to plasmacytoma expressed transript 2
  ENSRNOT00000007696   ENSRNOG00000005869   LOC498453      15:11865466--12045333     8.80749     0           −1.79769e+308        −1.79769e+308   4.27E−07      0.000156012   up              similar to transcription elongation factor A 1 isoform 2; transcription elongation factor A (SII) 1
  ENSRNOT00000016174   ENSRNOG00000012119   LOC690209      8:14245341--14246673      20.3598     6.87195     −1.56693             4.74563         2.08E−06      0.000614553   2.96            similar to NIMA (never in mitosis gene a) -related expressed kinase 2
  ENSRNOT00000004684   ENSRNOG00000003532   Magea11        X:144114831--144120816    2.56517     22.0279     3.1022               −7.82805        4.88E−15      9.30E−12      0.12            melanoma-associated antigen 11, similar to mage-k1
  ENSRNOT00000060426   ENSRNOG00000010477   Pomt1          3:11348785--11366632      0           5.56385     1.79769e+308         1.79769e+308    0.000173499   0.0227703     not expressed   Protein O-mannosyl-transferase 1
  ENSRNOT00000049814   ENSRNOG00000004819   Porcn          X:26317406--26330171      0           3.49927     1.79769e+308         1.79769e+308    0.000282208   0.0330933     not expressed   porcupine homolog
  ENSRNOT00000055971   ENSRNOG00000021780   Rad51l3        10:71092821--71107418     1.99246     0           −1.79769e+308        −1.79769e+308   0.000300691   0.0346468     up              DNA repair protein RAD51 homolog 4
  ENSRNOT00000066106   ENSRNOG00000008340   RGD1309779     8:67558903--67563530      0           8.1175      1.79769e+308         1.79769e+308    0.000454238   0.0474384     not expressed   Antifreeze protein, type I
  ENSRNOT00000063936   ENSRNOG00000033389   Susd2          20:13435256--13442683     2.35239     0           −1.79769e+308        −1.79769e+308   7.25E−07      0.000244074   up              sushi domain-containing protein 2
  ENSRNOT00000009762   ENSRNOG00000007428   Ypel4          3:67945701--67947571      0           2.48631     1.79769e+308         1.79769e+308    9.47E−05      0.0141986     not expressed   Protein yippee-like 4
  ENSRNOT00000048322   ENSRNOG00000029947   --             18:24386615--24444446     0.247115    285.439     10.1738              −15.0338        0             0             1155.085689     
  ENSRNOT00000059785   ENSRNOG00000027022   --             19:32261770--32521913     4.3896      40.097      3.19133              −3.74977        0.000176997   0.0231596     9.134545289     
  ENSRNOT00000041892   ENSRNOG00000031706   --             8:24852588--24853338      84.6196     39.8219     −1.08743             4.25664         2.08E−05      0.00423136    0.47059901      
  ENSRNOT00000048837   ENSRNOG00000033307   --             17:33352145--33352895     175.978     78.2828     −1.16863             5.17046         2.34E−07      9.39E−05      0.444844242     
  ENSRNOT00000016040   ENSRNOG00000011964   Abcd4          6:108660718--108681707    6.94143     14.753      1.08771              −3.61808        0.000296801   0.0343124     2.125354574     
  ENSRNOT00000024084   ENSRNOG00000017786   Acta1          19:54081497--54084508     2.69603     9.55081     1.82479              −4.1097         3.96E−05      0.00709345    3.542545892     
  ENSRNOT00000013286   ENSRNOG00000009951   Aif1l          3:11053195--11078079      31.4084     68.946      1.13432              −5.28738        1.24E−07      5.35E−05      2.195145248     
  ENSRNOT00000029137   ENSRNOG00000010877   Alg9           8:54131721--54194200      5.6306      0           −1.79769e+308        −1.79769e+308   2.91E−06      0.000811706   0               
  ENSRNOT00000022585   ENSRNOG00000016678   Angptl2        3:12147164--12345170      34.3392     15.3835     −1.15848             4.48941         7.14E−06      0.00175758    0.447986558     
  ENSRNOT00000025258   ENSRNOG00000018598   Ankrd1         1:240316122--240324804    8.98593     40.6488     2.17747              −7.96134        1.78E−15      3.66E−12      4.523605236     
  ENSRNOT00000065912   ENSRNOG00000007110   Ankrd6         5:49098943--49238039      1.20956     3.2422      1.42249              −3.50276        0.000460467   0.0478941     2.680478852     
  ENSRNOT00000027464   ENSRNOG00000020270   Anxa8          16:9715643--9730577       12.7852     25.2696     0.982934             −3.70747        0.000209344   0.0262431     1.976472797     
  ENSRNOT00000002857   ENSRNOG00000002095   Arhgap24       14:8026135--8346326       0.169448    2.00403     3.56399              −5.67541        1.38E−08      7.60E−06      11.82681413     
  ENSRNOT00000021801   ENSRNOG00000016066   Bambi          17:62654079--62658885     32.1927     58.4287     0.859944             −3.58421        0.000338099   0.0377975     1.814967368     
  ENSRNOT00000014267   ENSRNOG00000010698   Car1           2:88198729--88210693      1.61929     7.02468     2.11707              −4.11301        3.91E−05      0.0070206     4.338123499     
  ENSRNOT00000014180   ENSRNOG00000010079   Car3           2:88105881--88114721      9.18183     20.6693     1.17064              −3.76407        0.00016717    0.0221871     2.251108984     
  ENSRNOT00000008722   ENSRNOG00000006411   Cav2           4:42932126--42939501      20.3781     46.4948     1.19005              −5.04677        4.49E−07      0.000162733   2.281606234     
  ENSRNOT00000027084   ENSRNOG00000019939   CCND2_RAT      4:163524290--163546640    82.9549     153.687     0.889592             −4.0537         5.04E−05      0.00861661    1.852657287     
  ENSRNOT00000023977   ENSRNOG00000017819   Cd14           18:29374596--29376328     69.2244     34.7166     −0.995653            4.34566         1.39E−05      0.00304593    0.501508139     
  ENSRNOT00000021268   ENSRNOG00000015821   Cd2            2:196332589--196346221    1.12977     4.9592      2.13408              −3.51066        0.00044699    0.0468076     4.389566018     
  ENSRNOT00000038016   ENSRNOG00000027456   Cdc42bpg       1:209083956--209103885    2.00095     5.28006     1.39987              −4.52326        6.09E−06      0.00154558    2.638776581     
  ENSRNOT00000000628   ENSRNOG00000000521   Cdkn1a         20:7379385--7385595       229.484     392.911     0.77581              −3.70105        0.000214713   0.0268193     1.712149867     
  ENSRNOT00000035930   ENSRNOG00000026604   Cercam         3:8857698-−-8871398       0           0.866262    1.79769e+308         1.79769e+308    0.000195831   0.0249543     \#DIV/0!        
  ENSRNOT00000028440   ENSRNOG00000020952   Cgn            2:189644802--189663203    8.43665     18.6037     1.14085              −4.70097        2.59E−06      0.000736554   2.205105107     
  ENSRNOT00000048519   ENSRNOG00000000463   Col11a2        20:4924451--4953310       0.459021    0           −1.79769e+308        −1.79769e+308   5.68E−05      0.0094764     0               
  ENSRNOT00000016423   ENSRNOG00000011292   Col1a2         4:29393550--29428568      15.5644     2.90803     −2.42013             7.94696         2.00E−15      4.08E−12      0.186838555     
  ENSRNOT00000009985   ENSRNOG00000007234   CP51A_RAT      4:26752355--26770318      47.6671     24.0287     −0.988237            4.40456         1.06E−05      0.00244674    0.504094019     
  ENSRNOT00000068389   ENSRNOG00000016752   Crispld2       19:50283063--50378028     0.540175    0           −1.79769e+308        −1.79769e+308   0.000151645   0.020509      0               
  ENSRNOT00000025222   ENSRNOG00000018659   Csf1           2:203292764--203307965    21.2806     38.8832     0.869608             −4.00455        6.21E−05      0.0101341     1.827166527     
  ENSRNOT00000017310   ENSRNOG00000012896   Cyp2c11        1:243281319--243320945    0.956294    3.95536     2.04828              −3.9791         6.92E−05      0.0110682     4.136133867     
  ENSRNOT00000057522   ENSRNOG00000030213   D3ZEY5_RAT     8:72196263--72365798      0           0.674155    1.79769e+308         1.79769e+308    0.00028722    0.0334497     \#DIV/0!        
  ENSRNOT00000045362   ENSRNOG00000028910   D3ZKN0_RAT     3:105260698--105266080    15.4701     31.0881     1.00688              −3.9696         7.20E−05      0.0114333     2.009560378     
  ENSRNOT00000047772   ENSRNOG00000037380   D3ZQW7_RAT     1:88001743--88067218      8.48807     101.201     3.57565              −9.66754        0             0             11.92273391     
  ENSRNOT00000067423   ENSRNOG00000019770   D4A0X9_RAT     1:138189344--138202803    11.3313     22.6131     0.996847             −3.53674        0.000405097   0.0434354     1.995631569     
  ENSRNOT00000022899   ENSRNOG00000031743   D4A6I2_RAT     2:240527532--240541078    2.47696     0           −1.79769e+308        −1.79769e+308   3.74E−05      0.00678173    0               
  ENSRNOT00000007750   ENSRNOG00000005887   D4A6I7_RAT     7:112829665--112831373    19.5637     67.7496     1.79203              −4.05538        5.01E−05      0.00856585    3.46302591      
  ENSRNOT00000044096   ENSRNOG00000006028   D4A709_RAT     7:127403424--127423259    7.54706     3.1215      −1.27368             3.6294          0.000284081   0.0332428     0.413604768     
  ENSRNOT00000019301   ENSRNOG00000014293   D4AAV5_RAT     19:19757067--19833022     4.45908     0.611558    −2.86619             6.42977         1.28E−10      1.09E−07      0.137148919     
  ENSRNOT00000035977   ENSRNOG00000025883   D4AEE6_RAT     20:5379965--5391529       0.622497    2.91801     2.22885              −3.51577        0.000438474   0.0460199     4.687588856     
  ENSRNOT00000009402   ENSRNOG00000006787   Dhcr24         5:127637375--127662621    61.0847     26.911      −1.18261             4.89884         9.64E−07      0.000313358   0.440552217     
  ENSRNOT00000012532   ENSRNOG00000009291   Dnase1l3       15:18909362--18935342     2.46494     0.376542    −2.71067             4.16631         3.10E−05      0.00581839    0.152759094     
  ENSRNOT00000044776   ENSRNOG00000018121   E9PTW0_RAT     2:58667033--58720040      95.2285     0.746746    −6.99463             12.0933         0             0             0.007841623     
  ENSRNOT00000013608   ENSRNOG00000009439   Eef1a1         8:83463586--83466816      3935.43     3348.41     −0.233048            47.2063         0             0             0.850837139     
  ENSRNOT00000026303   ENSRNOG00000019422   Egr1           18:27343566--27347352     7.64836     1.50755     −2.34294             5.79267         6.93E−09      3.97E−06      0.197107615     
  ENSRNOT00000032780   ENSRNOG00000001469   Eln            12:23033656--23076086     314.631     137.942     −1.18959             4.48949         7.14E−06      0.00175758    0.438424694     
  ENSRNOT00000003615   ENSRNOG00000002664   Emp2           10:5311156--5348037       21.5151     44.9042     1.0615               −4.72352        2.32E−06      0.000673162   2.087101617     
  ENSRNOT00000005612   ENSRNOG00000004078   Eno3           10:57536964--57542311     32.2663     74.9383     1.21568              −5.23498        1.65E−07      6.89E−05      2.322494367     
  ENSRNOT00000019519   ENSRNOG00000013994   Enpp1          1:21223677--21287411      72.8494     33.2307     −1.1324              5.25403         1.49E−07      6.29E−05      0.456156125     
  ENSRNOT00000025663   ENSRNOG00000018982   Entpd3         8:125542933--125573945    0.250548    1.19274     2.25112              −3.66302        0.000249263   0.0299892     4.760524929     
  ENSRNOT00000019720   ENSRNOG00000014367   Ephb6          4:69316599--69331856      1.05752     0.0547861   −4.27073             3.85539         0.000115546   0.0166214     0.051806207     
  ENSRNOT00000000737   ENSRNOG00000000599   F1LTF8_RAT     20:43180812--43260729     0.0531117   0.35923     2.7578               −3.771          0.000162597   0.0216734     6.763669775     
  ENSRNOT00000040881   ENSRNOG00000015133   F1M0L3_RAT     8:47759174--47834586      2.94978     1.10333     −1.41874             3.57262         0.000353423   0.0390706     0.374038064     
  ENSRNOT00000059887   ENSRNOG00000039146   F1M2U4_RAT     11:53424952--53653313     11.4671     0.699976    −4.03405             4.7502          2.03E−06      0.00060442    0.061042112     
  ENSRNOT00000002814   ENSRNOG00000002053   F1M3H3_RAT     14:14309716--14565184     2.77457     5.27226     0.926158             −3.78463        0.00015394    0.0207583     1.90020796      
  ENSRNOT00000007876   ENSRNOG00000005986   F1M5X9_RAT     4:37617356--37880157      0.456827    6.47324     3.82477              −5.07286        3.92E−07      0.000146385   14.17000309     
  ENSRNOT00000052149   ENSRNOG00000019579   F1M6R5_RAT     8:61472271--61516975      0           3.44162     1.79769e+308         1.79769e+308    0.000221007   0.0273718     \#DIV/0!        
  ENSRNOT00000003320   ENSRNOG00000002403   Fam129a        13:66467072--66620137     4.96483     22.8277     2.20097              −8.30368        0             0             4.597881498     
  ENSRNOT00000056983   ENSRNOG00000006738   Fbxo32         7:94909567--94942444      0           1.83838     1.79769e+308         1.79769e+308    0.000205778   0.02596       \#DIV/0!        
  ENSRNOT00000004183   ENSRNOG00000003136   Fcrla          13:86775184--86785281     1.44194     7.54945     2.38836              −4.66781        3.04E−06      0.000848609   5.235620067     
  ENSRNOT00000065065   ENSRNOG00000043377   Fdps           2:181168902--181177792    172.389     95.1902     −0.856779            3.89786         9.70E−05      0.014446      0.552182564     
  ENSRNOT00000029284   ENSRNOG00000016050   Fgfr1          16:70869973--70910045     5.33782     1.3706      −1.96145             3.61352         0.000302063   0.0347329     0.256771491     
  ENSRNOT00000023144   ENSRNOG00000016818   Fgfr3          14:82683190--82697229     17.3903     61.7206     1.82747              −4.63187        3.62E−06      0.000987366   3.549139463     
  ENSRNOT00000006454   ENSRNOG00000004874   Flrt3          3:128922732--128934866    13.5093     37.2757     1.46429              −6.1661         7.00E−10      4.96E−07      2.759262138     
  ENSRNOT00000004382   ENSRNOG00000003183   Fmod           13:46987713--46998330     2.95122     0.329223    −3.16417             5.81051         6.23E−09      3.61E−06      0.111554882     
  ENSRNOT00000010712   ENSRNOG00000008015   Fos            6:109559134--109562001    43.9474     14.1807     −1.63185             6.18678         6.14E−10      4.48E−07      0.322674379     
  ENSRNOT00000045765   ENSRNOG00000018500   Frmd4a         17:84783243--85068101     3.93629     1.40724     −1.48396             3.55715         0.000374898   0.0409076     0.357504147     
  ENSRNOT00000004725   ENSRNOG00000003512   Gabra1         10:27258816--27313725     29.5779     12.5073     −1.24175             5.32286         1.02E−07      4.53E−05      0.422859635     
  ENSRNOT00000018252   ENSRNOG00000013090   Gadd45g        17:19230895--19232641     56.8067     113.132     0.993874             −4.31728        1.58E−05      0.00338489    1.991525648     
  ENSRNOT00000047019   ENSRNOG00000004290   Grb10          14:92814796--92911442     30.2417     15.0891     −1.00304             4.47503         7.64E−06      0.00186894    0.498950125     
  ENSRNOT00000023554   ENSRNOG00000016552   Hmgcs1         2:51737089--51753895      46.0965     21.5714     −1.09554             4.82166         1.42E−06      0.000438176   0.467961776     
  ENSRNOT00000028066   ENSRNOG00000020679   Icam1          8:20040164--20051949      56.3622     100.403     0.833005             −3.97193        7.13E−05      0.0113414     1.781388945     
  ENSRNOT00000020144   ENSRNOG00000014835   Il1rl1         9:39577878--39624781      0.470228    5.58205     3.56936              −6.50577        7.73E−11      6.89E−08      11.87094346     
  ENSRNOT00000009233   ENSRNOG00000006859   Insig1         4:2577468--2585691        39.7394     20.5991     −0.947991            4.01374         5.98E−05      0.00982828    0.51835458      
  ENSRNOT00000026706   ENSRNOG00000019711   Isoc1          18:54471689--54491596     49.9354     28.9799     −0.78501             3.52998         0.000415584   0.0443191     0.580347809     
  ENSRNOT00000015113   ENSRNOG00000043167   Itga9          8:123526903--123837993    8.67236     3.18275     −1.44615             4.45441         8.41E−06      0.00202076    0.366999294     
  ENSRNOT00000054983   ENSRNOG00000036703   Itgax          1:187396183--187416231    1.04124     3.27593     1.6536               −3.81958        0.000133681   0.0186697     3.146181476     
  ENSRNOT00000049292   ENSRNOG00000001706   Kalrn          11:68195339--68611336     0.548461    0           −1.79769e+308        −1.79769e+308   0.000360543   0.039747      0               
  ENSRNOT00000006930   ENSRNOG00000005206   Kcnq3          7:103325195--103364021    0.826586    0.134832    −2.616               4.16018         3.18E−05      0.00593781    0.163119143     
  ENSRNOT00000005382   ENSRNOG00000026371   Krt17          10:89185098--89189816     0.339747    2.42074     2.83291              −4.41           1.03E−05      0.00239402    7.125125461     
  ENSRNOT00000010660   ENSRNOG00000008057   Krt7           7:140160828--140175532    4.53148     12.9118     1.51064              −4.06718        4.76E−05      0.00823972    2.84935606      
  ENSRNOT00000012691   ENSRNOG00000009581   Lce1m          2:186053049--186054252    0.261279    3.64129     3.80078              −4.46855        7.88E−06      0.00190985    13.93640515     
  ENSRNOT00000013496   ENSRNOG00000009946   Ldlr           8:20824039--20846920      54.0272     26.6554     −1.01926             4.65674         3.21E−06      0.000888538   0.493370006     
  ENSRNOT00000022556   ENSRNOG00000016811   LOC100360880   1:78668540--78673167      7.47652     0.806406    −3.21279             5.58109         2.39E−08      1.24E−05      0.107858469     
  ENSRNOT00000000048   ENSRNOG00000000043   LOC100361089   14:1572617--1587520       5.22379     15.9721     1.61238              −3.89499        9.82E−05      0.014564      3.057569313     
  ENSRNOT00000040325   ENSRNOG00000021405   LOC100361547   1:244517580--245149649    0.423691    2.12941     2.32937              −3.66948        0.000243041   0.029496      5.025856107     
  ENSRNOT00000047694   ENSRNOG00000028826   LOC680161      4:151255240--151413220    2.72431     0.302578    −3.17051             3.87099         0.000108395   0.0157559     0.111065921     
  ENSRNOT00000043427   ENSRNOG00000031798   LOC682793      16:10475768--11202166     0           129.85      1.79769e+308         1.79769e+308    2.34E−06      0.000679557   \#DIV/0!        
  ENSRNOT00000050456   ENSRNOG00000029211   LOC685560      12:20872584--20874637     0.566721    2.99334     2.40104              −3.53543        0.000407118   0.0436082     5.281858269     
  ENSRNOT00000000707   ENSRNOG00000000579   Marcks         20:41306445--41309742     29.6393     14.8156     −1.0004              3.60827         0.000308242   0.0352683     0.499863357     
  ENSRNOT00000002512   ENSRNOG00000001827   Masp1          11:79532503--79615077     0.68297     2.82874     2.05027              −3.55578        0.000376856   0.0410568     4.141821749     
  ENSRNOT00000007577   ENSRNOG00000005695   Mgp            4:173910584--173913947    8.06788     1.58776     −2.3452              3.76003         0.000169895   0.0224737     0.196800151     
  ENSRNOT00000038212   ENSRNOG00000025764   Mt1a           19:11261630--11262647     92.2876     34.0727     −1.43752             3.67491         0.000237938   0.0290288     0.369201279     
  ENSRNOT00000066331   ENSRNOG00000028016   Ncf2           13:67806515--67834105     1.00012     0           −1.79769e+308        −1.79769e+308   0.000353333   0.0390706     0               
  ENSRNOT00000026212   ENSRNOG00000019322   Notch1         3:4631807--4675880        4.55959     8.24001     0.853742             −3.55739        0.000374551   0.0408858     1.807182225     
  ENSRNOT00000020532   ENSRNOG00000029792   Ogn            17:20987028--21007525     15.8048     42.463      1.42585              −6.04548        1.49E−09      1.00E−06      2.686715428     
  ENSRNOT00000060497   ENSRNOG00000039476   Pcdhb2         18:30104782--30107179     2.25469     0.482476    −2.2244              3.93859         8.20E−05      0.0126831     0.213987732     
  ENSRNOT00000011057   ENSRNOG00000008323   Pitpnm3        10:58903761--59017640     0.682975    2.85989     2.06605              −3.79939        0.000145053   0.0198391     4.18740071      
  ENSRNOT00000030329   ENSRNOG00000025587   Plagl1         1:7882673--7919508        68.9514     122.108     0.824511             −3.93646        8.27E−05      0.0127749     1.770928509     
  ENSRNOT00000016768   ENSRNOG00000011951   Plk2           2:41800744--41806503      34.0069     69.2133     1.02522              −4.82282        1.42E−06      0.00043661    2.035272254     
  ENSRNOT00000016991   ENSRNOG00000012495   Podxl          4:58611905--58658598      0.386863    0.0620132   −2.64118             3.70824         0.000208709   0.026187      0.160297573     
  ENSRNOT00000015972   ENSRNOG00000011500   Pou2af1        8:54534416--54561348      1.75792     5.39689     1.61826              −3.5917         0.000328529   0.0370255     3.070043005     
  ENSRNOT00000016628   ENSRNOG00000012364   Prickle2       4:126571460--126673011    2.17087     0.742499    −1.54781             3.91705         8.96E−05      0.0135983     0.342028311     
  ENSRNOT00000021010   ENSRNOG00000015643   Prph           7:137836151--137839931    20.8539     9.35111     −1.15711             4.05215         5.07E−05      0.00866355    0.448410609     
  ENSRNOT00000030007   ENSRNOG00000027839   Ptk2b          15:45589212--45718044     20.1607     37.1933     0.883494             −3.88276        0.000103278   0.015227      1.844841697     
  ENSRNOT00000052158   ENSRNOG00000008150   RGD1310552     8:79740524--79817585      4.21296     1.10341     −1.93286             3.54479         0.000392919   0.0423988     0.261908492     
  ENSRNOT00000051376   ENSRNOG00000018366   RGD1310819     9:36546065--36585558      6.67413     2.12089     −1.65391             3.75686         0.000172062   0.0226632     0.317777748     
  ENSRNOT00000022711   ENSRNOG00000016538   RGD1564327     17:86427198--86649274     0.438323    1.97388     2.17097              −4.78272        1.73E−06      0.000521287   4.503254449     
  ENSRNOT00000051671   ENSRNOG00000033358   RGD1564380     1:79964554--79966591      3.01913     11.7295     1.95793              −3.97989        6.89E−05      0.0110442     3.885059603     
  ENSRNOT00000047522   ENSRNOG00000029141   RGD1564942     5:134778160--134978965    1.09677     0.175426    −2.64432             3.52447         0.000424329   0.0449815     0.159947847     
  ENSRNOT00000032690   ENSRNOG00000023814   Rimklb         4:158901834--158936059    33.5082     14.199      −1.23873             3.91219         9.15E−05      0.0138141     0.423747023     
  ENSRNOT00000012811   ENSRNOG00000009656   Rspo1          5:144332301--144353646    5.06805     24.8367     2.29297              −6.96689        3.24E−12      3.86E−09      4.900642259     
  ENSRNOT00000028510   ENSRNOG00000020992   Selenbp1       2:189840449--189847639    2.66494     7.87451     1.56309              −3.65014        0.000262102   0.0312097     2.954854518     
  ENSRNOT00000022202   ENSRNOG00000016512   Sema3b         8:112845710--112852565    8.69307     21.0068     1.27292              −4.64465        3.41E−06      0.000936421   2.41649958      
  ENSRNOT00000001916   ENSRNOG00000001414   Serpine1       12:20931995--20942374     157.284     62.8455     −1.32349             6.23914         4.40E−10      3.29E−07      0.399567025     
  ENSRNOT00000020043   ENSRNOG00000014870   Slc13a5        10:59133557--59157617     0.621104    0.100966    −2.62097             3.58963         0.000331143   0.0371994     0.162558927     
  ENSRNOT00000027234   ENSRNOG00000019996   Slc16a1        2:199860320--199880639    87.5322     147.855     0.756294             −3.58662        0.00033499    0.0375052     1.689149821     
  ENSRNOT00000022383   ENSRNOG00000016147   Slc17a6        1:101425974--101466022    12.3913     5.21561     −1.24842             4.49859         6.84E−06      0.00169895    0.420909025     
  ENSRNOT00000012683   ENSRNOG00000009480   Slc24a3        3:134018774--134249326    14.6178     27.4457     0.908851             −3.87998        0.000104463   0.0153448     1.877553394     
  ENSRNOT00000066904   ENSRNOG00000004928   Sntg2          6:48059245--48263991      1.05054     0.185487    −2.50175             3.62119         0.000293248   0.0340006     0.176563482     
  ENSRNOT00000044424   ENSRNOG00000038091   Sohlh2         2:144406047--144428501    0.659867    3.37749     2.3557               −4.51754        6.26E−06      0.00158404    5.118440534     
  ENSRNOT00000038572   ENSRNOG00000023551   Sp6            10:85741420--85745602     0.0552052   0.65799     3.57519              −3.58626        0.000335459   0.0375326     11.91898589     
  ENSRNOT00000002499   ENSRNOG00000001823   St6gal1        11:79723268--79765638     4.20366     1.53518     −1.45324             3.61795         0.000296947   0.0343149     0.365200801     
  ENSRNOT00000007977   ENSRNOG00000006076   Steap2         4:25034175--25053800      13.3337     26.5595     0.994148             −4.18796        2.81E−05      0.00540252    1.991907723     
  ENSRNOT00000028675   ENSRNOG00000026951   Susd5          8:118701743--118739369    8.45529     2.62644     −1.68675             4.23269         2.31E−05      0.00460034    0.310626838     
  ENSRNOT00000019406   ENSRNOG00000014296   Syt10          7:128115442--128174488    0.159915    1.38967     3.11936              −4.32541        1.52E−05      0.00328267    8.690054091     
  ENSRNOT00000027474   ENSRNOG00000020279   Syt11          2:180873774--180897784    21.1451     9.49918     −1.15445             4.33742         1.44E−05      0.00314493    0.449237885     
  ENSRNOT00000024030   ENSRNOG00000017628   Tagln          8:48902208--48907693      599.341     1341.02     1.16188              −4.8862         1.03E−06      0.000330673   2.237490844     
  ENSRNOT00000055134   ENSRNOG00000026364   Tanc2          10:95145439--95318292     10.3312     5.12396     −1.01168             3.95866         7.54E−05      0.0118549     0.49596949      
  ENSRNOT00000027202   ENSRNOG00000020057   Tex101         1:79946338--79949053      5.06684     21.4094     2.07908              −5.08618        3.65E−07      0.000137773   4.225394921     
  ENSRNOT00000002867   ENSRNOG00000002093   Tgfbr3         14:3051038--3334311       2.74353     6.72919     1.2944               −3.92853        8.55E−05      0.0130724     2.452748831     
  ENSRNOT00000039221   ENSRNOG00000026607   Tnfsf18        13:77136963--77145251     11.558      35.8281     1.63221              −3.95677        7.60E−05      0.0119248     3.099852916     
  ENSRNOT00000025606   ENSRNOG00000018943   Tnnc1          16:6639356--6642331       38.374      109.038     1.50663              −5.00048        5.72E−07      0.000199665   2.841455152     
  ENSRNOT00000049000   ENSRNOG00000016731   Tpm2           5:59994101--60003261      239.823     427.958     0.835497             −3.59391        0.000325755   0.0368024     1.784474383     
  ENSRNOT00000028633   ENSRNOG00000021091   Trank1         8:115701553--115781013    0.208895    0.718386    1.78198              −3.53981        0.000400422   0.0430338     3.438981306     
  ENSRNOT00000017892   ENSRNOG00000013053   Trpm6          1:222382666--222502266    1.76725     4.12424     1.22262              −3.84319        0.000121444   0.0172997     2.333704909     
  ENSRNOT00000044425   ENSRNOG00000031707   Tuba3a         4:161396176--161405066    1.50508     8.84785     2.55549              −5.44118        5.29E−08      2.54E−05      5.878657613     
  ENSRNOT00000052352   ENSRNOG00000032967   Tuba3b         4:183289129--183294677    3.12467     18.4248     2.55987              −6.40278        1.53E−10      1.28E−07      5.896558677     
  ENSRNOT00000048874   ENSRNOG00000029071   Unc5c          2:239568541--239721231    0.429189    1.47456     1.7806               −4.09813        4.17E−05      0.00736355    3.435689172     
  ENSRNOT00000026559   ENSRNOG00000019598   Vegfa          9:10520729--10536068      3.82035     12.4068     1.69935              −3.81477        0.000136307   0.0189129     3.247555852     
  ENSRNOT00000013682   ENSRNOG00000010042   Wdfy2          15:42095911--42222222     0.698329    2.76484     1.98522              −3.49609        0.00047213    0.0488149     3.959222659     

MMP-7 regulates collagen expression via src, PKA, and ERK1/2
------------------------------------------------------------

Given the importance of collagen overexpression and deposition in chronic kidney dysfunction, we investigated the relationship between MMP-7 and collagen expression, focusing on *Col1a2* regulation, as the overexpression in the MMP-7 cell lines is higher, that is, a fourfold upregulation in the *Col1a2* as compared to twofold in *Col3a1*. Treatment with exogenous MMP-7 as well as conditioned medium from MMP-7 overexpressing cells caused upregulation of *Col1a2* expression in vector control cells (Fig. [4](#fig04){ref-type="fig"}A), further supporting the conclusion that MMP-7 increases collagen expression. To identify a pathway by which MMP-7 upregulates collagen, a range of signaling pathway inhibitors were used. Inhibition of PKA, PKC, PI3K, src, and MEK signaling both via p38 and ERK1/2 abrogated the MMP-7-induced stimulation of *Col1a2* expression (Fig. [4](#fig04){ref-type="fig"}B). Of two p38 inhibitors used, only SB203580 (4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole) abrogated *Col1a2* upregulation, but not the structurally similar 2-(4-Chlorophenyl)-4-(4-fluorophenyl)-5-pyridin-4-yl-1,2-dihydropyrazol-3-one. The PI3K inhibitor LY294002 had a more pronounced effect on *Col3a1* than *Col1a2* suggesting that the two collagens are regulated via different pathways ([Fig. 5](#fig05){ref-type="fig"}). Treatment with exogenous MMP-7 has been reported to induce activation by phosphorylation of Akt and ERK1/2 (p44/42 MAPK \[mitogen activated protein kinase\]) (Varro et al. [@b55]), as well as epithelial growth factor receptor (EGFR) and MEK (Tan et al. [@b52]). Increased src, PKA, and ERK1/2 phosphorylation was seen in the MMP-7 overexpressing cells compared to vector controls as assessed by immunofluorescence or in-cell Western blot analysis (Fig. [4](#fig04){ref-type="fig"}C). Importantly, phosphorylation was induced upon treatment with exogenous MMP-7 in vector control cells (Fig. [4](#fig04){ref-type="fig"}D). Taken together, these data suggest that MMP-7 regulates *Col1a2* expression via activation of ERK, p38, PKA, and src pathways.

![: MMP-7 activates src, PKA, and ERK1/2. (A) *Col1a2* is upregulated in NRK-52E vector control cells after 24-h treatment with exogenous human MMP-7 and conditioned medium (CM) from WT MMP-7 overexpressing cells. \**P* \< 0.05. (B) *Col1a2* upregulation in NRK-52E MMP-7 overexpressing cells is attenuated by inhibition of PI3K (LY294002, 25 μmol\\L), src (PP2, 1 μmol\\L), p38 (SB203580, 10 μmol\\L), ERK1/2 (FR180204, 5 μmol\\L), PKA/PKC (Staurosporine, 100 nmol\\L), and PKA (KT5720, 1 μmol\\L) at 24-h exposure. A second p38 inhibitor (2-(4-Chlorophenyl)-4-(4-fluorophenyl)-5-pyridin-4-yl-1,2-dihydropyrazol-3-one) failed to reproduce the inhibition of SB203508. \**P* \< 0.05. (C) Phosphorylation of ERK, src, and PKA increased in WT MMP-7 overexpressing NRK-52E cells compared to vector control cells as determined by immunofluorescent staining (top panels) and in-cell Western blot (bottom graph). \**P* \< 0.05. (D) Transient (2 h) MMP-7 treatment activates ERK, src, and PKA in vector control NRK-52E cells as determined by immunofluorescent staining for phosphospecific antibodies.](phy20001-e00090-f4){#fig04}

![MMP-7 induced up-regulation of Col1a2 and Col3a1 is regulated by distinct pathways as visible by differential responses to selected pathway inhibitors, specifically the PI3K inhibitor LY294002 and the src inhibitor PP2.](phy20001-e00090-f5){#fig05}

Discussion
==========

Chronic kidney disease is accompanied by excessive accumulation of extracellular matrix resulting in renal fibrosis. Fibrosis is a slow and incremental process resulting from repeated injury events accumulating over time. The process, which takes several decades in the human, is accelerated in the rat. As with the individual variability across the human population, the aging process between rat strains varies in respect to the kidney (Baylis and Corman [@b7]). The male F344 rat used in this study represents a population prone to developing CKD; we detected increased collagen deposition in these animals by 18 months.

MMP-7 \[aka matrilysin (Abramson et al. [@b1]), matrilysin-1, pump -- punctuated metalloproteinase (Woessner and Taplin [@b57]), pump-1 -- putative metalloproteinase 1 (Muller et al. [@b35]; Quantin et al. [@b38]), matrin (Miyazaki et al. [@b33])\] is the smallest member of the matrix metalloproteinase family. It is structurally different from other members of the MMP family in that it lacks the C-terminal hemopexin domain, and has instead an atypical sixth exon (Gaire et al. [@b18]). The protease is synthesized as a 30 kDa (267aa) inactive proform and is then stepwise activated to a final 18 kDa (177aa) form. MMP-7 is fully activated by trypsin and MMP-3, and is partially activated by plasmin, leukocyte elastase (Imai et al. [@b24]), or aminophenylmercuric acetate (APMA) in vitro. MMP-7 is expressed at very low levels in the adult, and only in a few tissues; however, it has gained attention due to its presence in a variety of disease states including cancer (Ramankulov et al. [@b39]) and CKD (Musial and Zwolinska [@b36]). In aging male Fisher 344 rats, MMP-7 was upregulated by over 500-fold in old animals compared to young. MMP-7 activity has been previously reported in association with fibrotic changes in the kidney (Catania et al. [@b12]) and other fibrotic conditions, such as idiopathic pulmonary fibrosis (Zuo et al. [@b64]; Rosas et al. [@b46]) and liver fibrosis (Huang et al. [@b23]). In these studies, we demonstrate a link between MMP-7 and collagen expression, suggesting a mechanistic link to fibrosis that is counterintuitive given the role of MMP-7 in degradation of the extracellular matrix (Fig. [5](#fig05){ref-type="fig"}).

We found that upregulation of MMP-7 in a normal rat cell-line NRK-52E results in upregulation of two collagen genes, *Col1a2* and *Col3a1*. Both genes are also upregulated in aging Fisher 344 rat kidneys. As *Col1a2* was upregulated fourfold and *Col3a1* only twofold, we focused our inhibitor experiments on type I collagen. In the MMP-7 overexpressing NRK-52E cells, we were able to inhibit the MMP-7-induced upregulation of *Col1a2* by using inhibitors against PKA, PI3K, src, p38, and ERK. When analyzing sequencing data, we were surprised to find no significant changes in expression in any of the major pathway members identified by the inhibitor screen (data not shown). However, it has been reported that inhibiting PI3K and MEK1/2 reversed the proliferative effects of MMP-7 in human gastric myofibroblasts by inhibiting phosphorylation of Akt and ERK1/2 (Varro et al. [@b55]). Exogenous MMP-7 treatment has also been reported to promote EGFR-activated MEK signaling, as demonstrated by increase in p-EGFR, p-MEK, and p-ERK in pancreatic cancer cells (Tan et al. [@b52]). We therefore investigated the effect of MMP-7 overexpression on activating phosphorylation status of ERK, src, and PKA. We found increased phosphorylation of each of these proteins in the MMP-7 overexpressing cells compared to vector control cells and we were also able to induce phosphorylation by exogenous MMP-7 treatment of vector control cells.

The human COL1A2 promoter has been described previously (Ramirez et al. [@b40]). Stimulation of transforming growth factor beta (TGFβ) signaling results in upregulation of Col1A2, via transmembrane serine/threonine kinases and intracellular Smad proteins (Massague et al. [@b30]). This requires the interactions of Sp1, Smad3/4 (Zhang et al. [@b63]), and p300/CREB-binding protein (Ghosh et al. [@b20]) on the COL1A2 promoter. MMP-7 has been implicated in the activation of EGFR and upregulation of TGFβ (Mimori et al. [@b32]). In the MMP-7 overexpressing cells, however, TGFβ expression was not altered, nor was that of any of the Smad proteins (data not shown). Thus, MMP-7 may be regulating Col1A2 via a non-TGF pathway.

While a paradoxical relationship between expression of MMP-7 and fibrosis has been demonstrated, putatively due to an aberrant wound healing response, (Huang et al. [@b23]; Wu and Chakravarti [@b58]; Rodder et al. [@b43]), a mechanistic link has not been delineated. Our data suggest that MMP-7 increases collagen expression in an autocrine fashion, independent of inflammation. This is consistent with the autocrine activation of ERK1/2 induced by MMP-2 (Xue and Jackson [@b60]). Our data suggest that the proteolytic activity of MMP-7 may not be required for induction of collagen expression, as the WT MMP-7, which is not processed to an active form in vitro results in elevated *Col1a2* and *Col3a1* expression. The fact that the collagen expression is higher in the WT than in the active mutant could result from the fact that there is significantly more total MMP-7 in the WT that in the active mutant, both at mRNA and secreted protein level. However, the fact that we do not see similar increases in collagen expression in the inactive mutant cell line does suggest a role for activation. Interestingly, in whole kidney lysates from the aging kidney, we have only observed pro-MMP-7 and not the active form, and we have not detected active MMP-7 by zymography in either kidney lysates or urine (data not shown). We conclude, based on the inability to detect active MMP-7 in the aging kidney, that pro-MMP-7 is upregulating collagen expression and, therefore, has a pathophysiological role in renal fibrosis. In addition, MMP-7 has not been reported to degrade Col1a2 and Col3a1. The only collagens demonstrated to be MMP-7 targets are collagen type 4 (Kraft et al. [@b26]) and collagen type 18 (Lin et al. [@b29]). However, MMP-7 activates the gelatinases MMP-2 and -9 (von Bredow et al. [@b11]), and the collagenases MMP-1 and -8, which in turn degrade collagen, but we have not detected MMP-8 expression in the rat kidneys, and MMP-1 expression decreases with age. We have also observed decreased total collagenase and increased gelatinase activity in the aging kidney (24 month) in whole kidney lysates (data not shown). Interestingly this effect is only observed in the presence of APMA to activate latent MMPs. Recent studies have shown that noncatalytic domains of MMPs have signaling effects (Correia et al. [@b15]; Mori et al. [@b34]; Vandooren et al. [@b54]), suggesting that noncatalytic functions of MMPs may have important implications. Although MMP-7 lacks many domains common to other MMPs, future studies will focus on identifying specific MMP-7 domains that mediate collagen overexpression.

In this study we demonstrate a mechanistic link between MMP-7 and fibrosis. The early upregulation of MMP-7 causes increased transcription of *Col1a2* and *Col3a1* genes primarily via PIK3, p38, ERK, src, and PKA signaling, leading to subsequent collagen deposition in the kidney.
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